viruses | pharmaphorum

Skip to main content

Thursday 7 November 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

viruses

R&D

COVID and influenza vaccines

Reconfiguring COVID and influenza vaccines for long-term eff...

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company's breakthrough vaccine technology, oligoDOM, and how it's driving the development of new influenza and SARS-CoV-2 vacc

News

Influenza Virus H1N1

Poolbeg licences candidate for broad-spectrum respiratory in...

Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections, such as influenza and coronavirus.

News

Coronavirus news

Trump pledges access to malaria drug chloroquine for COVID-1...

News

ViiV presses go on FDA filing for first-in-class HIV drug fostemsavir

ViiV presses go on FDA filing for first-in-class HIV drug fo...

News

Caucasian male with lack of sleep because he has flu stting in bed and ask for water or medicine. Concept ob being ill alone. Nobody can help him

Roche’s Xofluza limits spread of flu virus, says new study

News

HIV budding Color

ViiV’s first-in-class HIV drug on course for filings this ye...

Load more results

Editor's Picks

Novo Nordisk will file semaglutide for MASH next year

Eledon drug helps transplants 'cure' type 1 diabetes

UK Chancellor pledges £22bn rise in day-to-day NHS spending

Teva fined €462.6m for antitrust delay to MS drug rivals

Novartis pays $150m upfront for Monte Rosa degrader drug

News

Sarepta office

Sarepta pulls plug on Duchenne exon-skipping drug

Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

pushing two jigsaw pieces together

Enabling site success: Key insights to reducing burden and i...

Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company